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Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S310Conclusion: In conclusion, although a similar rate of attrition
was seen in donors overall, the reasons were different from
our previous study. Two of the changes instituted are likely
to have contributed (lowering joining age and increasing
BMI). Further work must be done on understanding other
factors associated with attrition, and collaborating with
other international registries to permit access to donors who
have moved to other countries.448
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Disease relapse, graft vs host disease and infection remain
the major barriers to successful allogeneic stem cell trans-
plantation. We previously presented data on the use of
escalated AUC based dosing of a continuous infusion (CI) of
IV busulfan over four days (Walko, BBMT, S218, 2012). In that
report, we described use of a test dose and day 1 and 4 PK
values to determine the dose delivered, and identiﬁed dose
limiting toxicities as rash and mucositis at an AUC of
8300 um-min/day and identiﬁed an AUC MTD of approxi-
mately 6912 uM-min/day x 4 days; a 40% increase over a
standard AUC dose of 4800 uM-min/day. Here we report
additional analyses to identify patients (pts) likely to beneﬁt
from this higher dose of continuous infusion busulfan.
Methods: Patients with advanced hematologic malignancies
and adequate organ function who were appropriate for a
MUD or MRD allogeneic transplant were enrolled on an IRB
approved trial of a test dose of busulfan (.8 mg/kg x 1) fol-
lowed by escalated dose busulfan (4800-8300 uM-min/d)
given as a 90 hour continuous infusion along with ﬂudar-
abine at 30 mg/m2/d x 5. Pts received tacrolimus and either
alemtuzamab (30), ATG + MTX (19) or MTX alone (6) as GVH
prophylaxis with standard anti-infective and supportive
care.
Results: 55 pts (median age 41, range 20-55) with myeloid
(38), lymphoid (8), or biphenotypic (1) leukemias, MDS or
MF (1) or lymphomas (7) were enrolled. All 55 subjects
were analyzed according to their being in the AUC low
(group 1, 19 pts), middle (group 2, 19 pts), or high dose
(group 3, 17 pts). 17 subjects had low, 20 had intermediate,
and 18 had high-risk disease by CIBMTR criteria. For the
entire group, univariate analysis identiﬁed age, recipient
CMV status, and disease risk as signiﬁcant factors for overall
(OS) and relapse free survival (RFS). Co-morbidity scores,
GVH occurrence or prophylaxis, donor/recipient sex and
donor type (MUD or MRD) were not signiﬁcant, nor was the
non-relapse mortality rate different between the three AUCgroups. Multivariable analysis identiﬁed CMV status as
borderline signiﬁcant (p¼.07), and high vs low AUC dose
(p¼.053) and disease risk (p¼.01) as signiﬁcant for both OS
and RFS. Outcomes were similar between AUC groups 2 and
3. Differences in OS and RFS were limited to the good and
intermediate risk patients as outcomes for high-risk pa-
tients were poor for all AUC groups (0/17 RFS and 1/17 OS).
When analyzing the 38 good and intermediate risk patients,
the OS and RFS were 66% and 62.5% for combined AUC
groups 2 and 3 compared to 31% (p¼.02) for both OS and
RFS in AUC group 1.
Conclusions: Targeted, PK based, CI busulfan that is
approximately 40% higher than standard doses can result in
apparent beneﬁt for patients with CIBMTR low or interme-
diate risk disease. These doses were unable to demonstrate
beneﬁt in high-risk patients for whom other approaches
such as immunotherapy, hypomethylating agents, or small
molecule inhibitors may be needed.449
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Several risk scores have been developed for the prediction
of transplant related mortality (TRM) following allogeneic
hematopoietic stem cell transplantation (HSCT). These have
been validated; however, predictive performance is sub-
optimal. In addition to inherent uncertainty in such a
complex medical procedure, methodological factors
impeding prediction might be attributed to the statistical
methodology, number and quality of features collected, or
simply the population size. Using an in-silico approach (i.e.
iterative computerized simulations), based on machine
learning (ML) algorithms, we set to explore the factors
limiting prediction.
ML is a subﬁeld of computer science and artiﬁcial intelli-
gence that deals with the construction and study of systems
that can learn from data, rather than follow explicitly pro-
grammed instructions. Commonly applied in complex data
scenarios, such as ﬁnancial and technological settings, it may
be suitable for outcome prediction of HSCT.
Study design involved two phases. The ﬁrst, focused on
development of several ML based prediction models of day
